Warning letters, 483s, Recalls, Import Alerts, Audit observations
USFDA Warning letter to Dupont cites inadequate evaluation of complaints, even though the Firm received several
USFDA Warning letter to Dupont cites inadequate OOS investigations, Root cause and CAPA, Impact evaluation. The warning letter
USFDA Warning letter to Dupont cites failure to ensure test methods are suitable, use of Non
USFDA Warning letter to Dupont cites inadequate change management program. The warning letter to Dupont Nutrition USA in
USFDA Warning letter to Dupont, USA cites inadequate laboratory controls, integrity of data and quality system does
USFDA Warning letter to Centrient India (Toansa, Punjab FEI 3004497364) in December 2022 cite method
USFDA Warning letter to Centrient India (Toansa, Punjab FEI 3004497364) in December 2022 cited inadequate
USFDA Warning letter to Centrient India (Toansa, Punjab FEI 3004497364) in December 2022 cited deficiencies in investigating
USFDA issued Warning letter to Glenmark, Goa, India facility (FEI 3004672766), cites lapses in procedure
In September 2022, USFDA issued a Warning letter to Lupin API facility at Tarapur, India
